Scienture Holdings, Inc.
SCNX · XNASCIK 1382574fmd_0Z0MFV7TCNZJ6YH66FPKB493PHManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Jun 30, 2026, 53 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 2 | 3 | 4 | 7 | 17 | 10 | 10 | 1 | 0 | 0 |
| Cost of revenue | 0 | – | 0 | 3 | 11 | 5 | 5 | 1 | 0 | 0 |
| Gross profit | 2 | 3 | 3 | 5 | 6 | 5 | 6 | 0 | 0 | 0 |
| Realized investment gains (losses) | – | – | – | (0) | – | – | – | – | – | – |
| Research and development | – | – | – | – | – | – | – | – | 2 | 2 |
| Total operating expenses | – | – | 3 | 5 | 8 | 10 | 8 | 4 | 15 | 43 |
| Operating income | (1) | 0 | (0) | 0 | (3) | (5) | (3) | (4) | (15) | (43) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 4 |
| Other non-operating income (expense) | – | – | – | – | – | (0) | 1 | (4) | (4) | (1) |
| Income before taxes | – | – | – | – | – | – | – | (8) | (19) | (44) |
| Income tax expense | – | – | – | – | – | – | – | – | (1) | (2) |
| Net income from continuing operations | (1) | 0 | – | – | – | – | (2) | (8) | (18) | (42) |
| Net income | (3) | 0 | 0 | (0) | (3) | (5) | (3) | (18) | 9 | (42) |
| Net income to common shareholders | – | – | – | – | (3) | (5) | (3) | – | – | – |